Desferrioxamine induced urinary iron excretion in thalassemia
Related Experiment Video
Updated: Nov 9, 2026

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
A P Dubey1, S Kumar, P Choudhury
1Department of Pediatrics, Maulana Azad Medical College, New Delhi.
Insights
This study on children with beta thalassemia major found that serum ferritin levels correlate with blood transfusions and iron excretion after desferrioxamine treatment. Many children achieved a negative iron balance with this therapy.
Area of Science:
- Pediatric Hematology
- Iron Chelation Therapy
- Metabolic Disorders
Background:
- Beta thalassemia major requires regular blood transfusions, leading to iron overload.
- Iron overload in beta thalassemia major can cause significant organ damage.
- Effective iron chelation therapy is crucial for managing patients.
Purpose of the Study:
- To evaluate the relationship between serum ferritin levels and iron excretion in children with beta thalassemia major undergoing desferrioxamine therapy.
- To assess the efficacy of subcutaneous desferrioxamine in achieving a negative iron balance.
Main Methods:
- Twenty-one children (2-14 years) with beta thalassemia major on regular transfusions received subcutaneous desferrioxamine.
- Measurements included serum ferritin, baseline 24-hour urinary iron excretion, and desferrioxamine-induced urinary iron excretion.
Main Results:
- A strong correlation was observed between serum ferritin levels and the total amount of blood transfusions received.
- Serum ferritin showed a good correlation with desferrioxamine-induced urinary iron excretion.
- Fifteen out of 21 children achieved a negative iron balance after a single dose of desferrioxamine.
Conclusions:
- Subcutaneous desferrioxamine therapy is effective in reducing iron overload in children with beta thalassemia major.
- Serum ferritin is a reliable indicator of iron burden and treatment response.
- Desferrioxamine therapy can help achieve a negative iron balance, mitigating complications of iron overload.
Abstract:
Twenty one children of beta thalassemia major aged between 2 and 14 years of age on regular blood transfusion were given subcutaneous desferrioxamine. Their serum ferritin, 24 hours baseline urinary iron excretion and subcutaneous desferrioxamine induced urinary iron excretion were measured. The result showed a close correlation between serum ferritin and amount of blood transfusions received by the patient. There was good correlation between serum ferritin and desferrioxamine induced urinary iron excretion. A negative iron balance could be achieved in 15 out of 21 children with one dose of desferrioxamine therapy.
Related Concept Videos
The Early Endosome: Endocytosis of Transferrin
Microbes and Other Elemental Cycles
Antiprotozoal Agents
Microbial Leaching
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
